Use Of Calcium Channel Blockers And Parkinson s Disease19

Use of Calcium Channel Blockers and Parkinson’s Disease19 The Pasternak et al publication was a Danish study that investigated the correlation between PD and CCB use via a retrospective cohort study using the Danish Civil Registration System, with an Oxford 2b level of evidence. The primary goal of this study was to determine if the incidence rate of PD in new users of DHPs differed significantly from those non-users, when studying the Danish population ≠¥45 years of age between January 1, 1998 and December 31, 2006. Researchers also hoped to evaluate PD rates among specific DHPs, non-DHP CCBs, as well as rates of dementia and death among patients on CCBs. Patients were excluded from the study if they had used a CCB within 2 years prior to the study, or had pre-existing PD or PD-related dementia at the study onset. Patients use of CCBs was stratified as: use (filling at least two consecutive prescriptions), past use, or 1 time use. PD diagnosis during the study was defined as those individuals who had at least one hospital diagnosti c code for PD in addition to receiving at least one prescription for antiparkinson dopaminergic therapy. Raw data was adjusted to account for sex, age, calendar year, and concomitant medication use. Propensity scores were calculated because researchers felt that baseline differences (comorbidities, concurrent medications, hospitalizations, socioeconomics, and geographic location). Logistic regression was used to determine these scores, which